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also appears to play a key role in
HSC homing and adhesion to the niche
(Stier et al., 2005), while blockade of
CD44 appears to block adhesion of
leukemic stem cells to the bone mar-
row microenvironment (Jin et al.,
2006).
Given the complex function of the
bone marrow stem cell niche, could
these critical adhesive and functional
signals from the niche cells be induced
only by the retrograde secretion or lo-
cal presentation of specific molecules
from HSCs? I.e., might HSCs con-
dition their niche (Taichman et al.,
2007)? Similarly, given these data,
why are prenatal HSCs THPO inde-
pendent? Are homologous signals,
which activate similar survival path-
ways in HSCs, secreted by embryonic
and fetal liver fibroblasts, or are fetal
HSCs fundamentally different from
postnatal HSCs? Similarly, one must
ask whether similar paradigms apply
to stem cells for other tissues, in other
organ-specific niches? And of course,
at a molecular level, why is mainte-
nance of a G0 pool required for long-
term support of HSC numbers?
Finally, it is always worthwhile to at-
tempt to draw tentative hypotheses
from elegant studies such as these
into the world of clinical hematology.
Would the provision of the proper
pharmacologic concentration of THPO
actually accelerate or quantitatively
enhance HSC engraftment after trans-
plantation? Conversely, would provi-
sion of anti-THPO antibody to patients
with acute leukemia release their
leukemic HSCs from the protection of
G0 retention, thus rendering them
more susceptible to anti-leukemic
ablative therapies? Such queries
could be directly tested in current im-
munodeficient mouse models, with
the potential for decisive clinical appli-
cation.
In summary, Qian et al. and Yoshi-
hara et al. present elegant and com-
pelling new data demonstrating a key
role for THPO in the maintenance of
the long-term repopulating, quiescent
HSC pool and furthermore suggest
that provision of THPO is at least one
of the unique contributions of osteo-
blasts after the transition of hemato-
poiesis from fetal liver to the bone
marrow. Clearly osteoblasts have
paid close attention to their musical
roots and ‘‘hold on loosely, but don’t
let G0.’’
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Two recent papers outline improvements in gene editing technology that may facilitate the analysis
of signaling networks important for development. The systems developed by both Thyagarajan and
coworkers (Thyagarajan et al., 2007) in Nature Biotechnology, and Lombardo and colleagues
(Lombardo et al., 2007) in Stem Cells, have the potential to advance our understanding of human
embryonic stem cells.The introduction of human embryonic
stem cell technology into the scientific
mainstream in 1998 brought with it the
possibility of cell-based therapy for600 Cell Stem Cell 1, December 2007 ª2conditions not treatable with available
pharmaceutical agents (Thomson
et al., 1998). Yet, 10 years on, the
stem cell field does not appear poised007 Elsevier Inc.to produce a therapeutic agent. How is
it that we, as a field, are still so far from
ourmark? One explanationmay be our
incomplete knowledge of the forces
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(A) The research groups led by Mario Capecchi
and Oliver Smithies were central to the devel-
opment of gene targeting technology based
on homologous recombination. In this system,
targeting occurs through recombination of
an exogenous DNA fragment containing a
mutated segment of a target gene flanked by
‘‘arm’’ segments that are identical to surround-
ing segments of the same gene. The ex-
ogenous, ‘‘donor’’ fragment also includes a
reporter element—frequently an antibiotic re-
sistance gene, here depicted as ‘‘res’’—to
allow selection of cells in which successful
recombination events have occurred. Only en-
dogenous cellular machinery is involved in this
process. This system allows for the insertion of
exogenous DNA segments into a host cell ge-
nome in multiple organisms, including mam-
mals. Martin Evans and coworkers applied
this homologous recombination technology to
mouse embryonic stem cells, allowing for the
introduction of edited gene segments into the
mouse germline. Drs. Capecchi, Evans, and
Smithies were awarded the 2007 Nobel Prize
in Physiology or Medicine for this contribution.
This technology has created a revolution in
mouse genetics but has been difficult to apply
to the human system.
(B) The site-specific gene editing system de-
veloped by Thyagarajan and coworkers is
based on the PhiC31 integrase, which cata-
lyzes site-specific integration events. Specifi-
cally, the PhiC31 integrase catalyzes a DNA
integration reaction only when it is simulta-
neously bound to two different cognate DNA
sequences: attB and attP. This is distinct
from the Flp and Cre recombinases, which rec-
ognize two identical DNA sites. Application of
PhiC31-mediated integration to the human
system is made possible by the presence of
multiple pseudo-attP sequences in the human
genome. The ‘‘donor’’ DNA segment in this
system contains a mutated target gene seg-
ment, as well as an attB site and a reporter
gene. The investigators use a GFP expression
cassette as well as an antibiotic resistance
gene as reporters. When this donor segment
and a PhiC31 integrase expression vector are
simultaneously introduced into a human cell,
the exogenous integrase is transiently ex-
pressed and catalyzes site-specific integration
events with reportedly high fidelity. Integration into the attP site is directional, as indicated through the presence of residual attL and attR sites.
(C) Lombardo and coworkers have developed a gene targeting strategy based on the use of engineered zinc finger nucleases (ZFNs). Simultaneous
introduction of expression vectors for two ZFNs (ZFN A and ZFN B), whose cognate DNA sequences flank a gene segment of interest, leads to tran-
sient expression of these proteins and the production of two double-stranded DNA breaks just upstream of the 50 end of the cognate sequences.
These breaks can be repaired via either nonhomologous end-joining (NHEJ) or homology-directed repair (HDR). If a donor DNA segment that is
homologous to the gene of interest is present, this donor is used as the template for HDR-mediated repair, leading to gene replacement. Mutations
in the ‘‘donor’’ sequence can be thus introduced into the chromosome.When ZFN cognate sequences are configured such that their 50 ends are distal
to the gene of interest, no residual sequence remains after HDR. As with the above-mentioned systems, reporter genes are included in the donor
fragment to allow for selection of successful integration events.that determine pluripotency and line-
age determination in embryonic stem
cells. Without more sophisticated un-
derstanding of stem cell biology and
the ontogeny of the cell lineages we
endeavor to repair, we are not likely
to approach our goal of producing
cell-based therapies.
One of the reasons why progress in
this area has been slow, despite inten-sive efforts, is the absence of an easily
implemented tool for dissecting the
myriad factors that define the identity
of stem cells. Technology for the tar-
geted modification of individual genes
based on homologous recombination,
a mainstay of investigation in molecu-
lar and cellular biology, has been ap-
plied to human embryonic stem cell
lines (Zwaka and Thomson, 2003). Un-Cell Stem Cell 1,fortunately, this system is labor inten-
sive and is not always reliable in the
human system. Therefore, this tech-
nique is not sufficiently facile to allow
for the high-throughput studies that
would be required to make significant
strides in the study of phenomena
as complex as lineage determination
and pluripotency. The use of trans-
genic technology to insert geneDecember 2007 ª2007 Elsevier Inc. 601
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the genome is technically more
straightforward and has been applied
successfully to complex developmen-
tal systems, such as the development
of networks between neurons in the
central nervous system (Livet et al.,
2007). The primary drawback of trans-
gene introduction using homologous
recombination or lentiviral technology
is the absence of control over site of
integration. The resultant, nonspecific
integration can disrupt genes, pro-
moters, or other chromosomal ele-
ments, leading to confounding tran-
scriptional effects. These confounders
are especially unpredictable in mam-
malian embryonic stem cells, given
their dynamic transcriptional and epi-
genetic states.
There is no question that improve-
ments in the technology of genetic
manipulation could potentially acceler-
ate progress in the study of both cis-
and trans-acting elements in human
embryonic stemcells. For example, the
engineering of reporter elements that
are under the control of developmental
stage-specific factors could be very
useful in the tracking of the behavior
of stem cells in culture. These reporter
elements could therefore aid the study
of signaling networks involved indevel-
opment and the testing of the prove-
nance of specific cell types.
We describe here two recently re-
ported gene editing tools that hold
significant promise. One of these tools,
created by Thyagarajan and cowork-
ers at Invitrogen and Cellartis, repre-
sents an improvement in ‘‘transgenic’’
integration technology (Thyagarajan
et al., 2007). The other tool described
here, created by Lombardo and co-
workers at Vita Salute San Raffaele
University and Sangamo BioSciences,
is a streamlinedmethod of gene-direc-
ted chromosome modification (Lom-
bardo et al., 2007).
Thyagarajan and coworkers report
a novel system for the introduction of
transgenes based on the bacterio-
phage C31 integrase (see Figure 1).
This integrase recognizes specific
attachment (attP) sites in host bacte-602 Cell Stem Cell 1, December 2007 ª2ria, and the chromosome modification
system based thereupon takes advan-
tage of the presence of many pseu-
doattachment (pseudo-attP) sites in
the human genome. Integration events
occur selectively at these sites and
can be identified through sequence
analysis of the genome. Therefore,
this technique allows for integration
events whose location is more predict-
able than with traditional transgenic
technology. In addition, this novel tool
appears to accommodate larger genes
than could be fit into vectors used as
part of traditional transgenic tech-
nology. Integration events produced
with all transgenic tools will tend to
occur more often in transcriptionally
active areas of the chromosome, or
‘‘hotspots.’’ Since attP sites occur fre-
quently in intronic sequences, the risk
of gene disruption may be lower than
with random integration. As the dis-
tance of attP sites with respect to
other chromosomal markers can be
measured, the silencing of specific in-
tegration sites can be used to map
shifts in transcriptionally active zones
in embryonic stem cells as they are
driven toward development into spe-
cific cellular lineages. This ability to
follow epigenetic phenomena repre-
sents a new utility for this tool, in addi-
tion to the study of the effects of single
genes.
Lombardo and coworkers have cre-
ated a gene editing tool based on site-
specific zinc finger nucleases (ZFNs).
The ZFNs used in this system are com-
prisedofaFokInucleasethat is targeted
to specific DNA sequences through fu-
sion with a sequence-specific, zinc fin-
ger DNA binding domain (see Figure 1).
TheZFNcreatesadouble-strandedbreak
in the chromosomal DNA that can be
repaired either through error-prone,
nonhomologous end joining (NHEJ) or
through faithful, homology-directed re-
pair (HDR) in theevent thatDNAofasim-
ilar sequence is available. Supply of an
engineered DNA sequence, similar to
the original sequence, in combination
with the ZFN is an elegant technique
for site-directed gene editing. This
ZFN-based gene replacement tool had007 Elsevier Inc.been reported previously but could not
be applied in multiple cell types due to
difficulties associated with efficient de-
livery of all the components of this sys-
tem into a single cell. The novel feature
of the system reported by Lombardo
and coworkers is the use of an inte-
grase-deficient lentiviral vector (IDLV)
to simultaneously deliver the ZFN and
the engineered DNA sequence into
cells. While a unique ZFN may need to
be designed for each specific locus,
this delivery tool appears to be more
efficient and reliable than homologous
recombination.
Both of the novel gene editing tools
described here represent significant
improvements over previously avail-
able systems. The relative simplicity
of these techniques and improved effi-
ciency of integration may allow investi-
gators to clear some of the hurdles as-
sociatedwith older technology. Both of
these new tools involve sequence-
directed gene editing, but both tech-
niques appear to exhibit somenonspe-
cific integration events. Therefore,
verification of individual integration
events is still required. It appears that
both of these tools will be very helpful
in scientific investigation, but it remains
to be seen whether they are ready for
direct use in patient-specific, cell-
based therapy.
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